Inhibikase Therapeutics (DB:IQT0) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

IQT0 Overzicht aandelen

A clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.

IQT0 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 90.16% per jaar groeien

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 14% per jaar dalen.

Heeft geen betekenisvolle marktkapitalisatie ( €7M )

Heeft een omzet van minder dan 1 miljoen USD ( $252K )

Aandelen zijn zeer illiquide

+ 3 meer risico's

Inhibikase Therapeutics, Inc. Concurrenten

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€31.0m

bioXXmed

XTRA:T5O

€1.0m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Inhibikase Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$0.56
52 Week Hoogtepunt	US$5.61
52 Week Laag	US$2.56
Bèta	0.78
11 maand verandering	0%
3 maanden verandering	-82.48%
1 Jaar Verandering	-89.58%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-98.26%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	IQT0	DE Biotechs	DE Markt
7D	0%	2.2%	-1.9%
1Y	-89.6%	-9.8%	12.3%

Rendement versus industrie: IQT0 presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -15.1 % opleverde.

Rendement versus markt: IQT0 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 13.8 % opleverde.

Prijsvolatiliteit

Is IQT0's price volatile compared to industry and market?
IQT0 volatility
IQT0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van IQT0 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van IQT0 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	7	Milton Werner	www.inhibikase.com

Inhibikase Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Inhibikase Therapeutics zich tot de beurswaarde?
IQT0 fundamentele statistieken
Marktkapitalisatie	€6.98m
Inkomsten(TTM)	-€18.01m
Inkomsten(TTM)	€238.24k

29.3x

P/S-verhouding

-0.4x

Koers/Winstverhouding

Is IQT0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IQT0 resultatenrekening (TTM)
Inkomsten	US$251.79k
Kosten van inkomsten	US$13.43m
Brutowinst	-US$13.17m
Overige uitgaven	US$5.86m
Inkomsten	-US$19.03m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-3.56
Brutomarge	-5,232.12%
Nettowinstmarge	-7,557.69%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde IQT0 op de lange termijn?

Bekijk historische prestaties en vergelijking

IQT0 Overzicht aandelen

Beloningen

Risicoanalyse

Inhibikase Therapeutics, Inc. Concurrenten

XTRA:CNW

€6.5m

XTRA:MDG1

€31.0m

XTRA:T5O

€1.0m

BST:BPXA

€772.4k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Recent updates

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.082 loss in 3Q 2020)

Inhibikase Therapeutics, Inc. Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.052 loss in 2Q 2020)

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell Microcap Value Index

Inhibikase Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

Full year 2020 earnings released: US$0.35 loss per share (vs US$0.70 loss in FY 2019)

Inhibikase Therapeutics, Inc. Announces Update on Phase 1 Clinical Trial of IkT-148009

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from NASDAQ Composite Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Inhibikase Therapeutics, Inc. Samenvatting